NLRP3 and metabolic dysfunction-associated steatohepatitis: However, since this approach lacks specificity and is likely to produce many off-target effects (Bahia et al., 2015), this study tested a novel selective NLRP3 antagonist for therapeutic effects in murine models of NASH.